Allopurinol
DrugCommercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
NCT Number: NCT01391325
This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Phase 4
Camperdown, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
Time frame: Every month for 6 months.
Proportion of subjects who experienced at least one Treatment Emergent Adverse Event (TEAE) during the study.
Time frame: Month 6
Proportion of subjects with serum urate (sUA) less than 6.0 mg/dL at Month 6 using Last Observation Carried Forward (LOCF) for subjects with missing values at Month 6.
Time frame: Every month for 6 months.
Proportion of subjects who experienced at least one gout flare requiring treatment during the study.
Time frame: Month 6
The SF-36 is a short-form health survey with 36 questions that yields an 8-scale profile of functional health and well-being scores as well as psychometrically-based physical (PCS) and mental health (MCS) summary. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability. The component scores (PCS and MCS) are norm-based to a standard population with a mean of 50 and a standard deviation of 10.
Ardea Biosciences, Inc.
Industry
Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO)
Acronym: LASSO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05499312
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Shatin, Hong Kong
View Trial DetailsNCT05665699
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06229145
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Birmingham, Alabama, United States
View Trial DetailsNCT06969469
Arthritis, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Taipei, Taiwan
View Trial Details